TR200102714T2 - Sikline bağımlı kinaz 2 ve IkB-&'nın pürün inhibitörleri - Google Patents

Sikline bağımlı kinaz 2 ve IkB-&'nın pürün inhibitörleri

Info

Publication number
TR200102714T2
TR200102714T2 TR2001/02714T TR200102714T TR200102714T2 TR 200102714 T2 TR200102714 T2 TR 200102714T2 TR 2001/02714 T TR2001/02714 T TR 2001/02714T TR 200102714 T TR200102714 T TR 200102714T TR 200102714 T2 TR200102714 T2 TR 200102714T2
Authority
TR
Turkey
Prior art keywords
alkyl
cycloalkyl
formula
ikb
hetaryl
Prior art date
Application number
TR2001/02714T
Other languages
English (en)
Inventor
T.Lum Robert
Lynn Blum Cheri
Mackman Richard
M.Wick Michael
R. Schow Steven
A. Zablocki Jeffrey
Ibrahim Prabha
Original Assignee
Cv Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics, Inc. filed Critical Cv Therapeutics, Inc.
Publication of TR200102714T2 publication Critical patent/TR200102714T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Asagidaki formüle sahip 2,6,9-trisübstitüe pürin bilesikleri açiklanmistir: FORMÜL: burada R1 halojen veya R'1-X dir, burada X=NH, -O-, tio veya sülfondur; R'1, sübstitüe edilmis veya edilmemis alkil, sikloalkil, heterosiklil, aril, heterohalka, hetaril, aralkil, heteroaralkil, alkil alkenil ve alkil alkinil, alkil sikloalkil veya alkil heterosiklildir; R2 sübstitüe edilmis veya edilmemis küçük alkil, sikloalkil, aril, heterohalka, hetaril, aralkil, heteroaralkil, heteroalkil, alkil alkenil ve alkil alkinil, alkil sikloalkil veya alkil heterosiklildir; R3, Halojen, hidroksil, tio, alkoksi, alkiltio, küçük alkil, -NR4R5 veya asagidaki formüle sahip bir bilesendir: FORMÜL. m,n ve o, bagimsiz olarak 1,2 veya 3 dür; Y ve R4', okzo, -NR4R5, hidroksi, tio, alkoksi, alkilto olusturulur; ve R4 ve R5 in herbiri, H, sübstitüe edilmis veya edilmemis alkil, sikloalkil, heterosiklik, aril, heterohalka, açil, hetaril, aralkil, heteroaralkil, heteroalkil, alkil alkenil, alkil DEVAMI VAR.
TR2001/02714T 1999-02-01 2000-01-20 Sikline bağımlı kinaz 2 ve IkB-&'nın pürün inhibitörleri TR200102714T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24122499A 1999-02-01 1999-02-01

Publications (1)

Publication Number Publication Date
TR200102714T2 true TR200102714T2 (tr) 2002-01-21

Family

ID=22909777

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02714T TR200102714T2 (tr) 1999-02-01 2000-01-20 Sikline bağımlı kinaz 2 ve IkB-&'nın pürün inhibitörleri

Country Status (26)

Country Link
EP (1) EP1150982B1 (tr)
JP (1) JP3681984B2 (tr)
KR (1) KR20010093308A (tr)
CN (1) CN1353713A (tr)
AR (1) AR029612A1 (tr)
AT (1) ATE306487T1 (tr)
AU (1) AU2969300A (tr)
BR (1) BR0007919A (tr)
CA (1) CA2361518A1 (tr)
CZ (1) CZ20012765A3 (tr)
DE (1) DE60023268T2 (tr)
DK (1) DK1150982T3 (tr)
ES (1) ES2246829T3 (tr)
GE (1) GEP20033092B (tr)
HK (1) HK1044334A1 (tr)
HU (1) HUP0200535A3 (tr)
IL (2) IL144675A0 (tr)
MX (1) MXPA01007851A (tr)
NO (1) NO327776B1 (tr)
NZ (1) NZ513371A (tr)
PL (1) PL350001A1 (tr)
RU (1) RU2001124352A (tr)
TR (1) TR200102714T2 (tr)
TW (1) TW538044B (tr)
UA (1) UA74142C2 (tr)
WO (1) WO2000044750A1 (tr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
ATE336484T1 (de) 1998-08-29 2006-09-15 Astrazeneca Ab Pyrimidine verbindungen
AU5438299A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
US7115589B2 (en) 1999-12-17 2006-10-03 Ariad Pharmaceuticals, Inc. Purine derivatives
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
EP1399446B1 (en) * 2001-06-27 2005-08-03 Cyclacel Limited 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders
EP1440072A4 (en) 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
AU2002357295A1 (en) * 2001-12-18 2003-06-30 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
CN1911460A (zh) 2002-02-15 2007-02-14 Cv医药有限公司 用于医用装置的聚合物涂层
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2003076434A1 (en) 2002-03-09 2003-09-18 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
US7476670B2 (en) 2003-02-18 2009-01-13 Aventis Pharma S.A. Purine derivatives, method for preparing, pharmaceutical compositions and novel use
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
NZ546611A (en) 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
EP1674467A1 (en) * 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
FR2880626B1 (fr) * 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
BRPI0609509A2 (pt) 2005-03-30 2010-04-13 Conforma Therapeutics Corp composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável
BRPI0610824A8 (pt) * 2005-05-16 2017-04-04 Prometic Pharma Smt Ltd Compostos derivados de purina, uso dos mesmos e composição contendo os referidos compostos
ES2336605T3 (es) * 2005-08-12 2010-04-14 Astellas Pharma Inc. Metodo para identificar la proteina diana de un agente y metodo para explorar un agente terapeutico para diabetes usando la proteina diana.
AU2006296386A1 (en) 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
GB0706632D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
MX389479B (es) 2011-09-02 2025-03-20 Incyte Holdings Corp Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k)
MD20140023A2 (ro) 2011-09-22 2014-06-30 Pfizer Inc. Derivaţi de pirolpirimidină şi purină
US9493464B2 (en) 2012-02-29 2016-11-15 The Scripps Research Institute Wee1 degradation inhibitors
EP2634190A1 (en) * 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CZ306894B6 (cs) * 2013-02-08 2017-08-30 Univerzita PalackĂ©ho v Olomouci 2-Substituované-6-biarylmethylamino-9-cyklopentyl-9H-purinové deriváty, jejich použití jako léčiva a farmaceutické přípravky tyto sloučeniny obsahující
CN104936959B (zh) * 2013-03-08 2018-09-18 中国人民解放军军事医学科学院放射与辐射医学研究所 2,6,9-三取代嘌呤衍生物及其制备方法与应用
US9879014B2 (en) * 2013-07-12 2018-01-30 Kyoto University Method for screening substance capable of inhibiting abnormal splicing causative of onset or progress of disease
FR3011240A1 (fr) * 2013-10-01 2015-04-03 Centre Nat Rech Scient Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
SG10201912302VA (en) 2015-02-27 2020-02-27 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
CN107235981B (zh) * 2017-05-25 2019-10-25 北京工业大学 低氧激活o6-苄基-2-硝基嘌呤衍生物及制法和应用
CN107903274A (zh) * 2017-12-28 2018-04-13 窦玉玲 一种胺类化合物及其在抗肿瘤药物中的应用
IL278889B2 (en) 2018-06-01 2025-11-01 Incyte Corp Dosing regimen for the treatment of pi3k related disorders
CN110256436B (zh) * 2019-06-27 2020-06-09 南京雷正医药科技有限公司 作为Trk激酶抑制剂的嘌呤类化合物
CN114981270B (zh) * 2019-09-20 2024-10-18 诺华公司 Mll1抑制剂和抗癌剂
CN117479944A (zh) * 2021-04-02 2024-01-30 泰州亿腾景昂药业股份有限公司 周期蛋白依赖性激酶抑制剂
WO2023016477A1 (en) * 2021-08-11 2023-02-16 Taizhou Eoc Pharma Co., Ltd. A cyclin-dependent kinase inhibitor
WO2023046128A1 (en) * 2021-09-27 2023-03-30 Taizhou Eoc Pharma Co., Ltd. A cyclin-dependent kinase inhibitor
AR131380A1 (es) 2022-12-16 2025-03-12 Astrazeneca Ab Purinas 2,6,9-trisustituidas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
WO1999007705A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases

Also Published As

Publication number Publication date
IL144675A0 (en) 2002-05-23
CA2361518A1 (en) 2000-08-03
NO20013751L (no) 2001-09-27
JP3681984B2 (ja) 2005-08-10
UA74142C2 (uk) 2005-11-15
CZ20012765A3 (cs) 2002-08-14
WO2000044750A1 (en) 2000-08-03
NZ513371A (en) 2003-08-29
EP1150982B1 (en) 2005-10-12
ATE306487T1 (de) 2005-10-15
PL350001A1 (en) 2002-10-21
RU2001124352A (ru) 2004-02-20
DE60023268T2 (de) 2006-06-01
TW538044B (en) 2003-06-21
CN1353713A (zh) 2002-06-12
GEP20033092B (en) 2003-10-27
DK1150982T3 (da) 2005-12-27
KR20010093308A (ko) 2001-10-27
IL144675A (en) 2008-11-26
HUP0200535A2 (hu) 2002-07-29
HUP0200535A3 (en) 2002-11-28
DE60023268D1 (de) 2006-03-02
EP1150982A1 (en) 2001-11-07
ES2246829T3 (es) 2006-03-01
NO327776B1 (no) 2009-09-21
AR029612A1 (es) 2003-07-10
HK1044334A1 (zh) 2002-10-18
AU2969300A (en) 2000-08-18
JP2002535405A (ja) 2002-10-22
NO20013751D0 (no) 2001-07-31
BR0007919A (pt) 2002-04-09
MXPA01007851A (es) 2003-06-04

Similar Documents

Publication Publication Date Title
ATE298572T1 (de) Purinhemmer von cyclin-abhängiger kinase 2 und ikappab-alpha
BR0308461A (pt) Derivados de pirimidina
PT1140851E (pt) 4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais
NZ240053A (en) Substituted methylene cyclopentyl-substituted purines and pyrimidines which exhibit antiviral activity
MX174406B (es) TIOXO HETEROCICLOS X1 o es alquileno (1-3C); en donde X1 es oxi, tio,(1-4C), alquenilo (3-4C) o alquinilo (3-4C); y en
DE69229114D1 (de) 1,2-substituierte 1h-imidazo[4,5-c]chinolin-4-amine
LU90908I2 (fr) Imatinib ou un de ses sels d'addition acide pharmaceutiquement acceptables en particulier le sel monométhanesulfonate (glivec)
EP0420511A3 (en) Heterocyclic derivatives
TR200402300T4 (tr) İmidazopirimidin türevleri ve triazolopirimidin türevleri.
DE69523574D1 (de) Carbapenem-derivate
RU98103160A (ru) Производные таксана
SE8204817L (sv) Tetrazinderivat
EP1070705A4 (en) Indole derivatives
PT1173411E (pt) Polialdiminas de derivados oligomericos de acido aminobenzoico e o seu uso na preparacao de poliureias curaveis por humidade e estaveis em armazenagem de um componente
WO2003068776A1 (en) [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
HUT42268A (en) Pesticide compositions containing pyrazolin-5-one derivatives and process for producing the active agents
WO2003011859A3 (en) Oxazolidinone derivatives as antibacterial agents
IE872143L (en) Pyrimidine derivatives
ATE64392T1 (de) Thiazolidin-4-one-derivate un deren saeureadditionssalze.
KR840006995A (ko) 화학적 방법
WO1997020814A1 (en) Propenone derivatives
GB926696A (en) Pyrimidine derivatives
YU46622B (sh) Postupak za proizvodnju derivata pirimidina
BR0108448A (pt) Derivados de tetraidrofuril óxi-e amino-substituìdos com atividade antitumor
BR0208440A (pt) Derivados de pirimidina-2,4,6-triona, processos para sua produção e agentes farmacêuticos contendo esses compostos